Hageman Factor C46T Promoter Gene Polymorphism in Patients with Hypercortisolism

Abstract

Glucocorticoids are a group of hormones with a particularly significant effect on hemostasis. In hypercortisolemic patients increased concentrations of II, VIII, and von Willebrand factors were reported. Considerably fewer studies were concerned with factor XII (FXII). There are reports of decreased FXII concentrations in both venous and arterial thrombosis patients. Also, it was determined that FXII C46T promoter gene polymorphism leads to changes of its concentration. The aim of the study was to determine the C46T polymorphism of FXII promoter gene in hypercortisolemic patients. Thirty hypercortisolemic patients were enrolled in the study. Twenty-nine healthy individuals served as controls. Genomic DNA was isolated from peripheral blood leukocytes. To analyse the polymorphism, PCR products were digested by Hga I at 37°C for 23 h, subjected to 2% agarose gel, and stained with ethidium bromide. In all subjects FXII activity was determined using a clot-based method. All statistical calculations were performed using STATA 12.0 software. A p-value lower than 0.05 was considered statistically significant. Prevalence of FXII C46T polymorphism did not differ significantly between hypercortisolemic patients and controls. No correlation was found between FXII activity and its gene promoter polymorphism in the hypercortisolemic group; however, a clear trend was recorded toward higher FXII activities in 46C homozygotes, and lower in 46T homozygotes. Mean FXII activities did not differ significantly between hypercortisolemic patients and the control group. It seems that in hypercortisolemic patients no significant disorders are present concerning FXII concentrations due to the C46T polymorphism of its gene promoter.

Key words

coagulation factor XII - Cushing’s syndrome - subclinical Cushing’s syndrome

• References

• 1 Świątkowska-Stodulska R, Babińska A, Sworczak K. Effect of selected hormones on particular parameters of hemostasis. Wiad Lek 2007; 60: 390-393 [Polish]
• 2 Świątkowska-Stodulska R, Babińska A, Sworczak K. Hypercortisolemia and hemostasis. Pol Merk Lek 2009; 152: 142-144 [Polish]
• 3 van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78: 481-488
• 4 Small M, Lowe GD, Forbes CD, Thomson JA. Thromboembolic complications in Cushing’s syndrome. Clin Endocrinol (Oxf) 1983; 19: 503-511
• 5 Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S, Kickler TS. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006; 118: 247-252
• 6 Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinol 1999; 10: 145-151
• 7 Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A. Increased factor VIII associated activities in Cushing’s syndrome: a propable hypercoagulable state. Thromb Haemost 1982; 47: 116-117
• 8 Ikkala E, Myllyla G, Pelkonen R, Rasi V, Viinikka L, Ylikorkala O. Haemostatic parameters in Cushing’s syndrome. Acta Med Scand 1985; 217: 507-511
• 9 Jacoby RC, Owings JT, Ortega T, Gosselin R, Feldman EC. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. Arch Surg 2001; 136: 1003-1006
• 10 Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A. Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 1985; 54: 518-520
• 11 Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul Fibrinol 1992; 3: 789-793
• 12 Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P. Hemostatic effects of stress hormone infusion. Anesthesiology 1994; 81: 1116-1126
• 13 Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I, Korsic M. Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009; 36: 70-74
• 14 Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105
• 15 Kastelan D, Dusek T, Kraljevict I, Aganovict I. Hypercoagulable state in Cushing’s syndrome in reversible following remission. Clin Endocrinol (Oxf) 2013; 78: 102-106
• 16 Stavrou E, Schimaier AH. Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis and thrombosis. Thromb Res 2010; 125: 210-215
• 17 Schmaier AH. The elusive physiologic role of factor XII. J Clin Invest 2008; 118: 3006-3009
• 18 Renne T, Schmailer AH, Nickel KF, Blombak M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-4303
• 19 Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunophatol 2010; 34: 31-41
• 20 Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 2004; 137: 459-464
• 21 Lessiani G, Falco A, Nicolucci E, Rolandi G, Davì G. Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. J Thromb Thrombolysis 2009; 27: 348-351
• 22 Pérez-Montes R, Sedano C, Yáñez L, Pérez-Puente A, Vallverdu H, Hernández JL, Iriondo A. Deep venous thrombosis, protein S deficiency and homozygous Factor XII 46T mutation. Eur J Pediatr 2005; 164: 591-593
• 23 Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G, Daurès JP, Quéré I, Dauzat M, Marès P, Gris JC. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. J Thromb Haemost 2007; 5: 700-707
• 24 Reuner KH, Jenetzky E, Aleu A, Litfin F, Mellado P, Kloss M, Jüttler E, Grau AJ, Rickmann H, Patscheke H, Lichy C. Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. Neurology 2008; 70: 129-132
• 25 Endler G, Mannhalter C, Sunder-Plassmann H, Lalouschek W, Kapiotis S, Exner M, Jordanova N, Meier S, Kunze F, Wagner O, Huber K. Homozygosity for the C→T polymorphism at nucleotide 46 in the 5′ untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol 2001; 115: 1007-1009
• 26 Endler G, Exner M, Mannhalter C, Meier S, Ruzicka K, Handler S, Panzer S, Wagner O, Quehenberger P. A common C→T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res 2001; 101: 255-260
• 27 Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, Mannhalter C, Hellstern P. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-296
• 28 Bohdanowicz-Pawlak A, Szymczak A, Waszczuk E, Bolanowski M, Bednarek-Tupikowska G. Subclinical Cushing’s syndrome in adrenal incidentalomas – possible metabolic consequences. Endokrynol Pol 2013; 64: 186-191
• 29 Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamaskai N, Niho Y. A common Genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014
• 30 Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, Felices R, Borrell M, Fontcuberta J. Association after linkage analysis indicates that homozygosity for the 46C→T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899-904
• 31 Kohler HP, Futers TS, Grant PJ. FXII (46C→T) polymorphism and in vivo generation of FXII activity – gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 8: 745-747
• 32 Girolami A, Scarparo P, Vettore S. The association of mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified. J Thromb Thrombolysis 2009; 27: 454-455
• 33 Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 2004; 17: 139-143
• 34 Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 3745-3751
• 35 Światkowska-Stodulska R, Kaniuka-Jakubowska S, Wiśniewski P, Skibowska-Bielińska A, Sworczak K. The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing’s syndrome. Eur J Endocrinol 2011; 165: 865-871